Another question is whether cytokines may be of benefit in patients with a higher tumor burden, e.g., more than three skeletal spots, used as the eligibility cut-off in this trial, Dr. Hero said.
Conference Coverage
IL-2 adds only toxicity to neuroblastoma antibody tx
